Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting
– Preclinical data demonstrate SER-155 reduces infection and Graft-versus-Host Disease –
“Microbiome-based therapeutics have the potential to protect medically compromised transplant patients from life-threatening infections and GvHD as they start on their road to recovery,” said
These results will appear on an e-poster (p194) and will be presented at
Across a variety of preclinical models, SER-155 appears to work by reducing gastrointestinal (GI) inflammation, fortifying the protective GI lining, and promoting immune cell balance in the gut. In cultured human cells designed to mimic the lining of the intestines, SER-155 protected the barrier between the colon and invading pathogens from inflammatory damage. In colon organoids – microscopic 3D collections of human cells that function as a tiny colon – SER-155 blocked several key inflammatory gene expression pathways linked with GvHD. In mice, SER-155 increased the ratio of regulatory T cells to inflammatory Th1 and Th17 effector T cells, which could potentially reduce the risk and severity of GvHD. Together, these platforms allow the researchers to pinpoint the potential immunomodulatory effects of gut microbes introduced by SER-155.
The SER-155 Phase 1b trial (ClinicalTrials.gov identifier: NCT04995653), which is being performed in collaboration with
According to published clinical data from Memorial Sloan Kettering, patients undergoing this type of transplant who have less diverse gut flora are significantly more likely than patients with a richer microbiome to experience infection or GvHD. The trial will help inform whether SER-155 can restore a healthy microbiome and support transplant recovery.
SER-155, an oral consortium of cultivated bacteria, is a microbiome therapeutic candidate in clinical development. SER-155 is designed using microbiome biomarker data from human clinical data, human cell-based assays, and in vivo disease models, with the aim to decrease infection and translocation of antibiotic-resistant bacteria in the gastrointestinal tract and modulate host immune responses to decrease GvHD. The rationale for this program is based in part on published clinical evidence from Seres’ collaborators at
For more information, please visit www.serestherapeutics.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the promise and potential impact of microbiome therapeutics, the ability of SER-155 to modulate host immune response or reduce death, the mechanism of action of SER-155, and the possibility that microbiome therapeutics may change the standard of car for any diseases.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; the impact of the COVID-19 pandemic; our unproven approach to therapeutic intervention; the lengthy, expensive and uncertain process of clinical drug development; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates and develop and commercialize our product candidates, if approved; and our ability to retain key personnel and to manage our growth. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the